论文部分内容阅读
背景:动脉粥样硬化常在症状出现前已较严重,目前尚不清楚治疗对于Framingham风险评分(FRS)较低的轻中度亚临床型动脉粥样硬化中年个体是否有益。目的:评估他汀类药物治疗2年能否延缓或逆转颈动脉内膜中层厚度(CIMT)的增加。设计、地点和参与者:2002年8月至2006年5月间在美国和欧洲的61个初级医疗中心进行一项随机、双盲、安慰剂对照研究M ETEO R(瑞舒伐他汀对颈动脉内膜中层厚度的疗效),共纳入984例个体,纳入标准为:年龄(平均年龄57岁)为其唯一的冠心病危险因素或10年FRS小于10%,CIM T中度增厚(1.2～3.5mm),
BACKGROUND: Atherosclerosis is often worse before the onset of symptoms. It is unclear whether the treatment is beneficial for middle-aged, mild-to-moderate subclinical atherosclerotic individuals with a lower Framingham risk score (FRS). PURPOSE: To assess whether statin treatment for 2 years can delay or reverse the increase in carotid intima-media thickness (CIMT). DESIGN, LOCATION AND PARTICIPANTS: A randomized, double-blind, placebo-controlled study of 61 primary care centers in the United States and Europe between August 2002 and May 2006 M ETEO R (rosuvastatin on carotid artery 984 individuals were enrolled in this study. The inclusion criteria were as follows: age (mean age 57 years) as the only risk factor for CHD or 10-year FRS less than 10%, moderate CIM T thickening (1.2 ~ 3.5mm),